Once again we have more evidence of failed treatment for Lyme disease indicating that we have an antibiotic resistant/tolerant superbug that does not respond to current antimicrobials. We need a cure to address this runaway plague not denial as the US Centers for Disease Control is responsible for this suffering worldwide. What has been deceitfully established here in the US has been propagated around the globe.
--------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov, jaucott2@jhmi.edu
Cc: (98 Undisclosed recipients)
Subject: Borrelia miyamotoi: 43 Cases Diagnosed in France by Real-Time PCR in Patients With Persistent Polymorphic Signs and Symptoms
To: the Tick-Borne Disease Working Group,
Please see the recent research paper below from Dr. Perronne in France. Once again we see direct detection methods identifying chronic Lyme disease in 43 patients just as Dr. Stricker identified chronic Lyme in twelve Canadian patients in 2018. https://www.dropbox.com/s/vlwecmbqpq1s97s/Middelveen%20et%20al.%202018%2C%20persistent%20Bb%20infection%20after%20antibiotics.pdf?dl=0
Further proof that what has been deceitfully established here in the US is having a ripple effect globally.
IDSA doctrine is now firmly entrenched in medical education and many young doctors are in denial about CLD/PTLDS or whatever; they really believe it’s all in your head if you don’t recover after two weeks of ABX. And without any real tests available to check what is going on, it is very easy to have this biased opinion confirmed with every new patient.
Ignoring public outcry and downplaying the severity of Lyme disease has paralyzed the response to this runaway plague.
We have a health crisis causing unimaginable pain and suffering and those who have controlled the narrative for the past three decades (with the financial support of the U.S. Centers for Disease Control) are %100 percent responsible GLOBALLY.
Frontiers in Medicine
28 February 2020
Borrelia miyamotoi: 43 Cases Diagnosed in France by Real-Time PCR in Patients With Persistent Polymorphic Signs and Symptoms
Michel Franck, Raouf Ghozzi, Julie Pajaud1, Nadou E. Lawson-Hogban1, Marie Mas, Alexis Lacout and Christian Perronne
https://www.frontiersin.org/articles/10.3389/fmed.2020.00055/full
Background: Borrelia species are divided into three groups depending on the induced disease and the tick vector. Borrelia miyamotoi is a relapsing fever Borrelia but can induce symptoms related to Lyme disease. Discovered in 1995, it is found in ticks around the world. In France, this species of Borrelia has been isolated in ticks and rodents, but was not yet observed in humans.
Objective: The aim of the study was to look for B. miyamotoi in symptomatic patients.
Methods: Real-time PCR was performed on 824 blood samples from patients presenting symptoms of persistent polymorphic syndrome possibly due to tick bite, a syndrome recognized by the French Authority for Health, which is close to the post-treatment Lyme disease syndrome. PCR was also performed on 24 healthy control persons. The primers were specifically designed for this particular species of Borrelia. The sequence of interest of 94 bp is located on the glpQ gene. Sequencing of amplification products, randomly chosen, confirmed the amplification specificity. To better investigate cases, a clinical questionnaire was sent to the patients PCR-positive for B. miyamotoi and to their physician.
Results: This search revealed a positive PCR for B. miyamotoi in the blood from 43 patients out of 824 (5.22%). PCR was negative in all control persons. A clinical chart was obtained from 31 of the 43 patients. A history of erythema migrans [bulls-eye rash] was reported in five of these 31 patients (16%). All patients complained about fatigue, joint pain and neuro-cognitive disorders. Some patients complained about respiratory problems (chest tightness and/or lack of air in 41.9%). Episodes of relapsing fever were reported by 11 of the 31 patients (35.5%). Chilliness, hot flushes and/or sweats were reported by around half of the patients. B. miyamotoi may not cross-react with B. burgdorferi serology.
Conclusion: This study is the first to detect B. miyamotoi in human blood in France. This series of human B. miyamotoi infection is the largest in patients with long term persistent syndrome. Our data suggest that this infection may be persistent, even on the long term.
Carl Tuttle
Lyme Endemic Hudson, NH